The American Diabetes Association’s Innovation Fund Invests in UpDoc to Accelerate the Future of AI-Driven Chronic Disease Management and Prevention

The American Diabetes Association (ADA) announced a strategic investment in UpDoc, a clinical AI company focused on revolutionizing chronic disease management using physician-grade AI technology.
The investment from the ADA’s Innovation Fund aims to validate UpDoc’s approach and accelerate the provision of AI-driven interventions for millions affected by diabetes and related conditions.
The ADA’s commitment to UpDoc signifies their conviction in the transformative potential of responsibly deployed clinical AI to bridge the gap between necessary and received care in chronic disease management.
Sharif Vakili, UpDoc’s CEO, highlighted the need for more continuous and proactive management of chronic diseases, positioning UpDoc’s AI agents to change the current health delivery model.
The partnership also underlines a broader trend among major health organizations using venture capital strategically to foster innovation that aligns with their mission.